These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31699828)

  • 1. Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma.
    Casey DL; Wexler LH; Pitter KL; Samstein RM; Slotkin EK; Wolden SL
    Clin Cancer Res; 2020 Mar; 26(5):1135-1140. PubMed ID: 31699828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee.
    Butel T; Karanian M; Pierron G; Orbach D; Ranchere D; Cozic N; Galmiche L; Coulomb A; Corradini N; Lacour B; Proust S; Guerin F; Boutroux H; Rome A; Mansuy L; Vérité C; Defachelles AS; Tirode F; Minard-Colin V
    Cancer Med; 2020 Apr; 9(8):2698-2709. PubMed ID: 32087612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.
    Teot LA; Schneider M; Thorner AR; Tian J; Chi YY; Ducar M; Lin L; Wlodarski M; Grier HE; Fletcher CDM; van Hummelen P; Skapek SX; Hawkins DS; Wagers AJ; Rodriguez-Galindo C; Hettmer S
    Cancer; 2018 May; 124(9):1973-1981. PubMed ID: 29461635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.
    Patel RR; Ramkissoon SH; Ross J; Weintraub L
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28338. PubMed ID: 32386112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma.
    Casey DL; Pitter KL; Wexler LH; Slotkin EK; Gupta GP; Wolden SL
    Br J Cancer; 2021 Aug; 125(4):576-581. PubMed ID: 34017087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond "Triton": Malignant Peripheral Nerve Sheath Tumors With Complete Heterologous Rhabdomyoblastic Differentiation Mimicking Spindle Cell Rhabdomyosarcoma.
    Hornick JL; Nielsen GP
    Am J Surg Pathol; 2019 Oct; 43(10):1323-1330. PubMed ID: 31107719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic profiling of pleomorphic rhabdomyosarcoma reveals a genomic signature distinct from that of embryonal rhabdomyosarcoma.
    Saoud C; Dermawan JK; Sharma AE; Tap W; Wexler LH; Antonescu CR
    Genes Chromosomes Cancer; 2024 May; 63(5):e23238. PubMed ID: 38722224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
    Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC
    Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelioid and spindle rhabdomyosarcoma with TFCP2 rearrangement in abdominal wall: a distinctive entity with poor prognosis.
    Li Y; Li D; Wang J; Tang J
    Diagn Pathol; 2023 Mar; 18(1):41. PubMed ID: 36998041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reappraisal of prognostic factors used in the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 study for localized rhabdomyosarcoma to optimize risk stratification and generate a prognostic nomogram.
    De Salvo GL; Del Bianco P; Minard-Colin V; Chisholm J; Jenney M; Guillen G; Devalck C; Van Rijn R; Shipley J; Orbach D; Kelsey A; Rogers T; Guerin F; Scarzello G; Ferrari A; Cesen Mazic M; Merks JHM; Bisogno G;
    Cancer; 2024 Jul; 130(13):2351-2360. PubMed ID: 38400828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent secondary genomic alterations in desmoplastic small round cell tumors.
    Chow WA; Yee JK; Tsark W; Wu X; Qin H; Guan M; Ross JS; Ali SM; Millis SZ
    BMC Med Genet; 2020 May; 21(1):101. PubMed ID: 32393201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
    Nagahashi M; Ling Y; Toshikawa C; Hayashida T; Kitagawa Y; Futamura M; Kuwayama T; Nakamura S; Yamauchi H; Yamauchi T; Kaneko K; Kanbayashi C; Sato N; Tsuchida J; Moro K; Nakajima M; Shimada Y; Ichikawa H; Lyle S; Miyoshi Y; Takabe K; Okuda S; Wakai T
    Breast Cancer; 2023 Jul; 30(4):584-595. PubMed ID: 36930419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
    Shern JF; Selfe J; Izquierdo E; Patidar R; Chou HC; Song YK; Yohe ME; Sindiri S; Wei J; Wen X; Rudzinski ER; Barkauskas DA; Lo T; Hall D; Linardic CM; Hughes D; Jamal S; Jenney M; Chisholm J; Brown R; Jones K; Hicks B; Angelini P; George S; Chesler L; Hubank M; Kelsey A; Gatz SA; Skapek SX; Hawkins DS; Shipley JM; Khan J
    J Clin Oncol; 2021 Sep; 39(26):2859-2871. PubMed ID: 34166060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
    Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
    Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
    Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: The French experience.
    Pondrom M; Bougeard G; Karanian M; Bonneau-Lagacherie J; Boulanger C; Boutroux H; Briandet C; Chevreau C; Corradini N; Coze C; Defachelles AS; Galmiche-Roland L; Orbach D; Piguet C; Scoazec JY; Vérité C; Willems M; Frebourg T; Minard V; Brugières L
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28486. PubMed ID: 32658383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhabdomyosarcoma: How Advanced Molecular Methods Are Shaping the Diagnostic and Therapeutic Paradigm.
    Giannikopoulos P; Parham DM
    Pediatr Dev Pathol; 2021; 24(5):395-404. PubMed ID: 34107813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.